Transcription of Practical risk-based guide for managing data integrity
{{id}} {{{paragraph}}}
1. ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE. Practical risk-based guide for managing data integrity Version 1, March 2019. 2. PREAMBLE. This original version of this guidance document has been compiled by a subdivision of the APIC data integrity Task Force on behalf of the Active Pharmaceutical Ingredient Committee (APIC) of CEFIC. The Task Force members are: Charles Gibbons, AbbVie, Ireland Danny De Scheemaecker, Janssen Pharmaceutica NV. Rob De Proost, Janssen Pharmaceutica NV. Dieter Vanderlinden, Ajinomoto Omnichem Andr van der Biezen, Aspen Oss Sebastian Fuchs, Tereos Daniel Davies, Lonza AG. Fraser Strachan, DSM. Bjorn Van Krevelen, Janssen Pharmaceutica NV. Alessandro Fava, (Fabbrica Italiana Sintetici) SpA.
1.4 Overall Data Integrity Approach . When assessing data integrity risks within an organisation, companies may focus immediately on those systems or areas that are the most obvious in this context, such as a particular software, a specific lab system or instrument etc. Doing so creates the risk of forgetting less visible but still
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}